Iptacopan (LNP023) is a first-in-class, oral, low molecular weight, Factor B inhibitor being developed for the treatment of diseases associated with activation alternative complement pathway. Current Phase III studies iptacopan include paroxysmal nocturnal hemoglobinuria, C3 glomerulonephritis, IgA nephropathy, and atypical hemolytic uremic syndrome. Preclinical identified CYP2C8, OATP P-gp as ...

precursors and progenitors to increase production of fetal hemoglobin. J Clin Invest 75: 547-557, 1985 51. Rosa RM, Bierer BE, Thomas R, Jeffrey BS, Stoff JS, Kruskall M, Robinson S, Bunn HF, Epstein FH: A study of induced hyponatremia in the prevention and treatment of sickle-cell crisis. New Eng J Med303: 1138-1143, 1980 52. Leary M, Abramson N: Induced hyponatremia for sickle-cell crisis. Ne...